Bausch Health Companies Inc. (TSE:BHC – Get Free Report)’s share price shot up 24.6% during trading on Thursday. The stock traded as high as C$12.09 and last traded at C$12.05. Approximately 1,815,131 shares were traded during trading, an increase of 234% from the average daily volume of 544,187 shares. The stock had previously closed at C$9.67.
Key Bausch Health Companies News
Here are the key news stories impacting Bausch Health Companies this week:
- Positive Sentiment: Stronger-than-expected quarterly performance: Bausch Health reported C$2.52 in earnings per share and approximately C$4.19 billion in quarterly revenue. Reports characterized third-quarter profit as higher than the prior-year period and described the results as an earnings beat. Bausch Health Companies Inc. Q3 Profit Climbs
- Positive Sentiment: Raised or reaffirmed growth expectations: Management indicated 2026 revenue of roughly $5.525 billion to $5.625 billion, giving investors greater visibility into the company’s full-year performance. Bausch Health signals 2026 revenue guidance
- Positive Sentiment: Share buyback supports the stock: The board authorized a repurchase of up to C$70 million of shares, or approximately 1.9% of the outstanding stock. The authorization may signal that management views the shares as undervalued and could provide incremental support for per-share results. Bausch Health share buyback report
- Neutral Sentiment: Management commentary remains important: The earnings call focused on operating performance, the full-year outlook and product-specific trends, giving investors additional detail on the company’s execution and financial priorities. Bausch Health Q3 2026 earnings call transcript
- Negative Sentiment: Xifaxan could weigh on the fourth quarter: Bausch Health warned of Q4 headwinds for Xifaxan, creating a near-term risk to sales and potentially limiting the upside from the strong third-quarter results. Xifaxan headwinds and 2026 outlook
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to MarketBeat, Bausch Health Companies has a consensus rating of “Hold”.
Bausch Health Companies Trading Up 25.4%
The company has a debt-to-equity ratio of -1,173.29, a quick ratio of 0.58 and a current ratio of 1.44. The firm has a market cap of C$4.54 billion, a price-to-earnings ratio of -4.13, a P/E/G ratio of 0.21 and a beta of 0.82. The company’s 50-day moving average is C$8.65 and its 200-day moving average is C$7.93.
Bausch Health Companies (TSE:BHC – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported C$2.52 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. The company had revenue of C$4.19 billion during the quarter. On average, research analysts predict that Bausch Health Companies Inc. will post 5.55 earnings per share for the current year.
Bausch Health Companies declared that its board has initiated a share buyback program on Wednesday, October 28th that authorizes the company to buy back C$70 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 1.9% of its stock through open market purchases. Share buyback programs are usually a sign that the company’s board believes its shares are undervalued.
About Bausch Health Companies
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Recommended Stories
- Five stocks we like better than Bausch Health Companies
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
